Form 4: Iterum Therapeutics Director Buys 6,000 Shares

Iterum Therapeutics plc Director Michael W. Dunne acquired 6,000 ordinary shares at $0.3652 per share, increasing his beneficial ownership.

Summary

• Michael W. Dunne, a Director of Iterum Therapeutics plc, purchased 6,000 ordinary shares.
• The transaction occurred on November 18, 2025.
• The shares were acquired at a price of $0.3652 per share.
• Following this transaction, Mr. Dunne beneficially owns 241,001 ordinary shares.

Sentiment

Score: 7

Explanation: The purchase of shares by a director generally indicates confidence in the company's future, which is a positive signal for investors. The transaction size is moderate.

Positives

• A company director, Michael W. Dunne, purchased 6,000 ordinary shares, indicating confidence in the company's future prospects.
• The purchase price of $0.3652 per share suggests a belief in the current valuation.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Michael W. Dunne, a Director of Iterum Therapeutics plc, acquired 6,000 ordinary shares from the open market on November 18, 2025, at a price of $0.3652 per share.

Stakeholder Impact

• Shareholders: May view the director's purchase as a positive signal of management confidence, potentially influencing investor sentiment and share price.
• Employees: No direct impact on employment terms, compensation, or operations is indicated by this insider transaction.
• Customers: No direct impact on product offerings, services, or customer relationships is indicated.
• Suppliers: No direct impact on supply chain relationships or agreements is indicated.
• Creditors: No direct impact on the company's debt obligations or creditworthiness is indicated by this transaction.

Key Dates

Recommendation

A director's purchase of shares is a positive indicator of internal confidence in the company's prospects. However, this single transaction, while notable, does not provide sufficient information to warrant a 'buy' or 'sell' recommendation without a broader analysis of the company's financial health, market position, and strategic outlook. Investors should consider this as a supportive data point within their overall due diligence.

Keywords

Iterum Therapeutics, ITRM, Insider Trading, Director Purchase, Share Acquisition, Beneficial Ownership, SEC Form 4